 WESTLAKE VILLAGE, Calif., Dec. 06, 2021 GLOBE NEWSWIRE -- MannKind Corporation Nasdaq: MNKD, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021. During the event, the Companys Chief Executive Officer, Michael Castagna, PharmD, will be participating in a webcasted Fireside Chat discussing its vision for 2022 and Mr. Castagna and the Companys Chief Financial Officer, Steven B. Binder will be conducting 1x1 virtual investor meetings. 